Equity
€97,910 from €168,614 in 2016
Equity fell by 42% in 5 years.
PHARMA SERVICES
Overview
Lifetime
15 annual accounts with figures on one time axis, 21 filings since 2001peak €78,797 (2012)
€29,446▼ 22.8%
lowest -€20,174 (2011)
-€332▲ €3
peak €168,614 (2016)
€97,910▼ 0.3%
€9,263▼ 0.8%
peak 1.3 FTE (2021)
1.3 FTE▲ 18.2%
Board2 names since 2015
1 directorGestifar
Owners2 names in the annual accounts
66%ETS. VANDERELST and 1 other
Documentsfilings and deeds
28-06-202233 days before the deadline
2021financial year
Gross margin from €38,125 to €29,446Loss of €332Staff from 1.1 FTE to 1.3 FTEMerger proposal: to be absorbed by Gestifar 01-07Cash from €44,979 to €15,674
Key points
from the 2021 annual accounts, the last ones filedLosses
-€667 in two years
The 2020 and 2021 financial years closed with a loss. 2020 was the heaviest.
Filings
21 annual accounts since 2001
Five of the last ten came late. The 2019 accounts came latest: 35 days after the end of the period.
No score
Board and ownership
- ETABLISSEMENT VANDERELST SRL consolidatesscore 70equity €444,329 (2025) · annual accounts 2021
Recent changes
Merger: absorbed by GESTIFAR
Dissolution of the company · Dissolved without liquidation · General meeting of 17-06-2022 · Gazette deed
Merger proposal: to be absorbed by Gestifar
Capital from €61,973.38 to €218,038.77, 630 new shares · Permanent representative: Jean-Christophe Vanderelst · Legal-form conversion: from public limited company to private limited company · Gazette deed
Incorporation
21 publications in the Belgian Official Gazette, the last on 14-07-2022 · Gazette deed
Official details
Source: KBO- Status
- Absorbed by GESTIFARmerger by absorption, July 2022
- Activity
- “La société a pour objet le conseil pharmaceutique et le contrôle de la qualité,l'achat,la…” (deed in French)From the articles, 6 activitiesNo NACE code in the KBO yet
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 2021
- Financial year end
- 31 December
- Peppol
- Not found in the Peppol Directory
Annual accounts 2021
- €29,446▼ 22.8%
- ≈ €110,000estimated
- €332▼ 0.8%
- €97,910▼ 0.3%
- €107,173▼ 0.4%
- 1.3 FTE▲ 18.2%
- Filing
- Filed on 28-06-2022
Insights on PHARMA SERVICES
Absorbed by GESTIFAR in July 2022. The last annual accounts are for financial year 2021. The company was dissolved without liquidation.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette.
Financials
Annual accounts 2021
full format, filed on 28-06-2022, 33 days before the deadline€29,446
▼ 22.8%
-€42
▲ €54
-
-
91.4%
unchanged
11.57
▲ 0.05
The turnover shown is an estimate from the gross margin.
Turnover ≈ €110,000. Estimated: probably between €56,000 and €200,000.
Money flows
no detail for 2021Balance sheet
balance sheet total €107,173 on 31-12-2021What the company ownsHow it is paid for
in euro
in euro
Staff
€22,415
Staff costs divided by the average number of full-time equivalents.
-2 people
people who joined
people who left
In 2021, 2 people joined and 4 left.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet: assets | ||||||||||||||||
20/58 |
107,173 | 107,584 | 108,425 | 110,067 | 187,711 | 177,323 | 168,924 | 125,252 | 121,439 | 114,923 | 89,183 | 104,730 | 97,763 | 88,112 | 101,632 | |
21/28 |
- | - | - | - | - | - | - | - | - | - | - | - | 2,914 | 5,827 | 8,741 | |
22/27 |
- | - | - | - | - | - | - | - | - | - | - | - | 2,914 | 5,827 | 8,741 | |
29/58 |
107,173 | 107,584 | 108,425 | 110,067 | 187,711 | 177,323 | 168,924 | 125,252 | 121,439 | 114,923 | 89,183 | 104,730 | 94,850 | 82,285 | 92,891 | |
40/41 |
91,499 | 62,605 | 43,443 | 22,486 | 32,717 | 109,598 | 155,612 | 107,472 | 91,926 | 63,711 | 21,443 | 26,311 | 20,386 | 17,894 | 8,647 | |
40 |
74,175 | 32,605 | 43,025 | 19,815 | 32,260 | 80,595 | 126,255 | 68,620 | 41,180 | 33,514 | 12,600 | 25,500 | 20,142 | 17,540 | 8,000 | |
41 |
17,324 | 30,000 | 418 | 2,671 | 457 | 29,003 | 29,357 | 38,852 | 50,746 | 30,197 | 8,843 | 811 | 244 | 354 | 647 | |
54/58 |
15,674 | 44,979 | 64,983 | 87,581 | 154,994 | 67,725 | 13,066 | 17,780 | 29,513 | 51,212 | 65,881 | 76,401 | 74,463 | 64,391 | 84,244 | |
490/1 |
- | - | - | - | - | - | 246 | - | - | - | 1,858 | 2,019 | - | - | - | |
| Balance sheet: equity and liabilities | ||||||||||||||||
10/49 |
107,173 | 107,584 | 108,425 | 110,067 | 187,711 | 177,323 | 168,924 | 125,252 | 121,439 | 114,923 | 89,183 | 104,730 | 97,763 | 88,112 | 101,632 | |
10/15 |
97,910 | 98,242 | 98,577 | 98,024 | 87,774 | 168,614 | 146,962 | 110,265 | 107,119 | 95,658 | 74,568 | 94,742 | 87,079 | 71,268 | 83,538 | |
10/11 |
18,550 | 18,550 | 18,550 | 18,550 | 18,550 | 110,000 | 110,000 | 218,039 | 218,039 | 218,039 | 218,039 | 218,039 | 218,039 | 218,039 | 218,039 | |
100 |
- | - | 18,550 | 18,550 | 18,550 | 110,000 | 110,000 | 218,039 | 218,039 | 218,039 | 218,039 | 218,039 | 218,039 | 218,039 | 218,039 | |
13 |
1,855 | 1,855 | 1,855 | 1,855 | 1,855 | 3,000 | 1,900 | - | - | - | - | - | - | - | - | |
130/1 |
1,855 | 1,855 | - | - | - | - | - | - | - | - | - | - | - | - | - | |
130 |
- | - | 1,855 | 1,855 | 1,855 | 3,000 | 1,900 | - | - | - | - | - | - | - | - | |
1311 |
1,855 | 1,855 | - | - | - | - | - | - | - | - | - | - | - | - | - | |
14 |
77,505 | 77,837 | 78,172 | 77,619 | 67,369 | 55,614 | 35,062 | -107,774 | -110,920 | -122,381 | -143,471 | -123,297 | -130,960 | -146,771 | -134,501 | |
17/49 |
9,263 | 9,342 | 9,848 | 12,043 | 99,937 | 8,709 | 21,962 | 14,988 | 14,320 | 19,265 | 14,615 | 9,988 | 10,684 | 16,844 | 18,094 | |
17 |
- | - | - | - | - | - | - | - | - | - | - | - | - | 3,997 | 7,208 | |
170/4 |
- | - | - | - | - | - | - | - | - | - | - | - | - | 3,997 | 7,208 | |
42/48 |
9,263 | 9,342 | 9,848 | 12,043 | 99,937 | 8,709 | 21,962 | 14,988 | 14,320 | 19,265 | 14,615 | 9,988 | 9,235 | 12,847 | 10,886 | |
42 |
- | - | - | - | - | - | - | - | - | - | - | - | 3,997 | 3,211 | 3,054 | |
44 |
3,698 | 102 | 667 | 1,308 | 390 | 106 | 15,450 | 10,905 | 10,476 | 11,145 | 12,156 | 5,902 | - | - | 3,304 | |
440/4 |
3,698 | 102 | 667 | 1,308 | 390 | 106 | 15,450 | 10,905 | 10,476 | 11,145 | 12,156 | 5,902 | - | - | 3,304 | |
45 |
5,565 | 9,240 | 9,182 | 10,735 | 8,097 | 8,603 | 6,247 | 4,083 | 3,844 | 8,120 | 2,459 | 3,636 | 4,756 | 9,636 | 4,527 | |
450/3 |
304 | 1,277 | 921 | 1,610 | - | 1,426 | 2,959 | - | - | 2,482 | 1,278 | 1,790 | 1,569 | 1,005 | 1,594 | |
454/9 |
5,262 | 7,963 | 8,261 | 9,125 | 8,097 | 7,177 | 3,288 | 4,083 | 3,844 | 5,638 | 1,181 | 1,846 | 3,187 | 8,631 | 2,933 | |
47/48 |
- | - | - | - | 91,450 | - | 265 | - | - | - | - | 450 | 481 | - | - | |
492/3 |
- | - | - | - | - | - | - | - | - | - | - | - | 1,449 | - | - | |
| Income statement | ||||||||||||||||
70 |
- | - | - | - | - | - | - | - | - | - | 69,421 | 69,421 | 68,595 | - | - | |
76A |
- | - | - | - | - | - | - | - | 272 | - | - | - | - | - | - | |
9900 |
29,446 | 38,125 | 42,185 | 52,936 | 48,848 | 57,376 | 57,688 | 39,678 | 44,865 | 78,797 | 9,147 | 36,164 | 37,679 | 69,276 | 48,287 | |
60/61 |
- | - | - | - | - | - | - | - | - | - | 64,632 | 36,715 | 34,431 | - | - | |
62 |
29,140 | 37,873 | 40,208 | 41,496 | 37,842 | 35,329 | 20,212 | 36,261 | 33,469 | 57,779 | 23,776 | 21,877 | 19,294 | 79,690 | 32,228 | |
630 |
- | - | - | - | - | - | - | - | - | - | - | 2,331 | 2,914 | 2,914 | 2,914 | |
640/8 |
348 | 348 | 423 | 348 | 348 | 348 | 348 | 348 | 366 | 1,455 | 5,971 | 3,827 | 874 | 773 | 621 | |
66A |
- | - | - | - | - | - | 75 | - | - | 115 | 345 | 733 | 110 | - | 130 | |
9901 |
-42 | -96 | 1,555 | 11,093 | 10,659 | 21,699 | 37,128 | 3,070 | 11,030 | 19,563 | -20,600 | 8,129 | 14,598 | -14,101 | 12,525 | |
75/76B |
- | - | 0 | - | 12 | 12 | 42 | 134 | 371 | 1,908 | 817 | 496 | 1,675 | 2,360 | 947 | |
75 |
- | - | 0 | - | 12 | 12 | 42 | 134 | 371 | 1,908 | 817 | 496 | 1,675 | 2,360 | 947 | |
65/66B |
121 | 83 | 81 | 70 | 60 | 59 | 133 | 57 | 207 | 106 | 45 | 229 | 352 | 529 | 640 | |
65 |
121 | 83 | 81 | 70 | 60 | 59 | 133 | 57 | 207 | 106 | 45 | 229 | 352 | 529 | 640 | |
9903 |
-163 | -178 | 1,474 | 11,023 | 10,610 | 21,652 | 36,962 | 3,146 | 11,466 | 21,250 | -20,174 | 7,663 | 15,811 | -12,270 | 12,702 | |
67/77 |
169 | 156 | 921 | 773 | 1 | - | - | - | 5 | 160 | - | - | - | - | - | |
9904 |
-332 | -335 | 553 | 10,250 | 10,610 | 21,652 | 36,962 | 3,146 | 11,461 | 21,090 | -20,174 | 7,663 | 15,811 | -12,270 | 12,702 | |
9905 |
-332 | -335 | 553 | 10,250 | 10,610 | 21,652 | 36,962 | 3,146 | 11,461 | 21,090 | -20,174 | 7,663 | 15,811 | -12,270 | 12,702 | |
| Appropriation of the result | ||||||||||||||||
9906 |
77,505 | 77,837 | 78,172 | 77,619 | 66,224 | 56,714 | -70,812 | -107,774 | -110,920 | -122,381 | -143,471 | -123,297 | -130,960 | -146,771 | -134,501 | |
14P |
77,837 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
791/2 |
- | - | - | - | 1,145 | - | 107,774 | - | - | - | - | - | - | - | - | |
691/2 |
- | - | - | - | - | 1,100 | 1,900 | - | - | - | - | - | - | - | - | |
6920 |
- | - | - | - | - | 1,100 | 1,900 | - | - | - | - | - | - | - | - | |
| Social balance sheet | ||||||||||||||||
9087 |
1.3 | 1.1 | 1.1 | 1.2 | 1.2 | 1 | 1.1 | 1 | 1 | 0.4 | 0.4 | 0.4 | 0.4 | 1.2 | 0.5 | |
Hours worked1013 |
680 | 1,119 | 1,207 | 1,261 | 1,176 | 1,085 | 618 | - | 1,096 | 1,123 | 708 | 640 | 646 | 2,213 | 890 | |
| Document | ||||||||||||||||
The accounts for 6 older financial years (2001-2006) were filed as documents without figures as data, scans for example.
The notes to these accounts have 1 item. You find them in the filed accounts (PDF).
Source: Annual accounts 2021 (PDF), filed on 28-06-2022.
Filings
each dot is a set of accounts, on the day it reached the National Bank| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2021 | full format | 28-06-2022 | 2022-20105849 | |
| 31-12-2020 | full format | 19-08-2021 | 2021-52700069 | |
| 31-12-2019 | full format | 04-09-2020 | 2020-52000563 | |
| 31-12-2018 | micro format | 23-07-2019 | 2019-39000067 | |
| 31-12-2017 | micro format | 23-08-2018 | 2018-50800210 | |
| 31-12-2016 | micro format | 18-08-2017 | 2017-44700493 | |
| 31-12-2015 | full format | 23-08-2016 | 2016-46400361 | |
| 31-12-2014 | full format | 17-06-2015 | 2015-18300090 | |
| 31-12-2013 | full format | 18-06-2014 | 2014-18900012 | |
| 31-12-2012 | full format | 27-06-2013 | 2013-23000510 | |
| 30-06-2011 | full format | 12-01-2012 | 2012-00800366 | |
| 30-06-2010 | full format | 01-02-2011 | 2011-02300113 | |
| 30-06-2009 | full format | 02-03-2010 | 2010-06000178 | |
| 30-06-2008 | full format | 18-02-2009 | 2009-05100246 | |
| 30-06-2007 | full format | 08-01-2008 | 2008-00800249 | |
| 30-06-2006 | full format | 26-02-2007 | 2007-05800743 | |
| 30-06-2005 | full format | 30-01-2006 | 2006-03400909 | |
| 30-06-2004 | full format | 28-01-2005 | 2005-03402233 | |
| 30-06-2003 | full format | 24-12-2003 | 2003-85304486 | |
| 30-06-2002 | full format | 16-04-2003 | 2003-10800166 | |
| 30-06-2001 | full format | 19-03-2002 | 2002-06805190 |
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | 10,459 | 17,511 | -11,187 | 15,438 | ||
| - | - | - | - | - | - | - | - | - | - | - | 9,994 | 18,724 | -9,356 | 15,615 | ||
| - | - | - | - | - | - | - | - | - | - | - | 2,331 | 0 | 0 | - | ||
| -29,305 | -20,003 | -22,598 | -67,413 | 87,269 | 54,659 | -4,714 | -11,733 | -21,699 | -14,669 | -10,520 | 1,938 | 10,072 | -19,853 | - | ||
| 97,910 | 98,242 | 98,577 | 98,024 | 87,774 | 168,614 | 146,962 | 110,265 | 107,119 | 95,658 | 74,568 | 94,742 | 85,615 | 69,438 | 82,005 | ||
| - | - | - | - | - | - | - | - | - | - | -29.7% | 11.7% | 21.3% | - | - | ||
| 91.4% | 91.3% | 90.9% | 89.1% | 46.8% | 95.1% | 87.0% | 88.0% | 88.2% | 83.2% | 83.6% | 90.5% | 89.1% | 80.9% | 82.2% | ||
| 11.57 | 11.52 | 11.01 | 9.14 | 1.88 | 20.36 | 7.69 | 8.36 | 8.48 | 5.97 | 6.10 | 10.49 | 10.27 | 6.41 | 8.53 | ||
| 0.09 | 0.10 | 0.10 | 0.12 | 1.14 | 0.05 | 0.15 | 0.14 | 0.13 | 0.20 | 0.20 | 0.11 | 0.12 | 0.24 | 0.22 | ||
| -0.3% | -0.3% | 0.6% | 10.5% | 12.1% | 12.8% | 25.2% | 2.9% | 10.7% | 22.0% | -27.1% | 8.1% | 18.2% | -17.2% | 15.2% | ||
| -0.3% | -0.3% | 0.5% | 9.3% | 5.7% | 12.2% | 21.9% | 2.5% | 9.4% | 18.4% | -22.6% | 7.3% | 16.2% | -13.9% | 12.5% | ||
| - | - | - | - | - | - | - | - | - | - | 66 days | 134 days | 107 days | - | - | ||
| - | - | - | - | - | - | - | - | - | - | 69 days | 59 days | - | - | - |
EBIT margin: not included in this filing.
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Social balance sheet
| Item | 31-12-2021 |
|---|---|
| 1.3 | |
| Joined | 2 |
| Left | 4 |
Source: social balance sheet in the 2021 annual accounts
Insights on PHARMA SERVICES
The operating result for 2021 is a loss of €42, smaller than the loss of €96 in 2020.
Debt's share of the balance-sheet total stays at 8.6%.
Board & ownership
Last board
1 director, last change in 2021Mandates through the years
2 names, the dashed line is todayGestifar
Sole director
Sole director
Jean-Christophe Vanderelst
Sole director
Sole director
BoardEarliermandate already running before its first mentionend not dated
Mandates as a list
- Gestifar
- Sole director, from 30-09-2015 to date
- Jean-Christophe Vanderelst
- Sole director, from before 01-07-2021, no longer listed in the 2021 annual accounts
Control
Consolidating parent
Equity €444,329
Profit €458 in 2025 (profit €8,174 in 2024)
Checked score 70
Source: parent in own accounts 2021
consolidates
This company
PHARMA SERVICES
Equity €97,910
Loss €332 in 2021
Capital
- Contribution
- €18,550
- Shares
- 1,251
- Contribution per share
- €14.83
- Equity per share
- €78.27 in 2021
- Source
- 2021 annual accounts
Owners through the years
as the annual accounts name themOwners as a list
- ETS. VANDERELST
- GESTIFAR
Source: lists of holdings in the owners' accounts
Articles of association
deed of 01-07-2021 (in French)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
Capital transactions
Shareholders according to the deeds
At incorporation
deed of 01-07-2021 ↗
- Gestifar (BE 0441.670.890) sole founder · 100% at incorporation
Capital over time
- 01-07-2021 Incorporation · €31,011.48 · 1,251 shares
- 01-07-2021 Incorporation · €61,973.38 · 250 shares
- 01-07-2021 Capital increase of €156,065.39 · to €218,038.77 · 630 new shares · in kind
- 01-07-2021 Capital reduction of €108,038.77 · to absorb losses
- 01-07-2021 Capital reduction of €91,450 · repaid to the shareholders
Network & group
Parent
ETABLISSEMENT VANDERELST SRL
Checked score 700433.063.032 · equity €444,329 · profit €458 (2025)
Acquisitions and mergers
1 transactionTaken over by:GESTIFAR
Connections & network
1 last directorThe network starts from the directors of PHARMA SERVICES. Every other company they run is a node.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Timeline
Timeline
32 events since 2000Capital
Filings
Financial
End
200020052010201520202025
2022
Merger: absorbed by GESTIFARDissolution of the company · Dissolved without liquidation · General meeting of 17-06-20222 points ▸
- General meeting, 17-06-2022
- Accounting effect, 01-01-2022
- The deed holds 8 more points.
Annual accounts 2021 filed PDFfull format · 33 days before the deadline
2021
Annual accounts 2020 filed PDFfull format · 19 days late
Merger proposal: to be absorbed by GestifarCapital from €61,973.38 to €218,038.77, 630 new shares · Permanent representative: Jean-Christophe Vanderelst · Legal-form conversion: from public limited company to private limited company11 points ▸
- Accounting effect, 01-01-2021
- Legal-form conversion, from public limited company to private limited company, mentioned twice in the deed
- Capital, €62,000, 1,251 shares
- Founding capital, €31,011.48, 1,251 shares
- Capital increase, €30,988.52
- Capital, €18,550, 880 shares
- Founding capital, €61,973.38, 250 shares
- Capital increase, €156,065.39
- Capital decrease, €108,038.77
- Capital decrease, €91,450
- Permanent representative, Jean-Christophe Vanderelst
- The deed holds 11 more points.
2020
Annual accounts 2019 filed PDFfull format · 35 days late
2019
Annual accounts 2018 filed PDFmicro format · 8 days before the deadline
2018
Liquidity more than quadruples current ratio 9.14 The current ratio rises from 1.88 to 9.14. Short-term debt falls from €99,937 to €12,043.
Annual accounts 2017 filed PDFmicro format · 23 days late
2017
Annual accounts 2016 filed PDFmicro format · 18 days late
2016
Liquidity more than doubled current ratio 20.36 The current ratio rises from 7.69 to 20.36. Short-term debt falls from €21,962 to €8,709.
Equity above €150,000 equity €168,614 ▲14.7% After 5 profitable years in a row, equity reaches €168,614.
Annual accounts 2015 filed PDFfull format · 23 days late
2015
Highest result from 2007 to 2021 net €36,962 ▲1,075% The operating result of €37,128 and the net result of €36,962 are both a record.
Annual accounts 2014 filed PDFfull format · 44 days before the deadline
2014
Annual accounts 2013 filed PDFfull format · 43 days before the deadline
2013
Equity above €100,000 equity €107,119 ▲12% After 2 profitable years in a row, equity reaches €107,119.
Annual accounts 2012 filed PDFfull format · 34 days before the deadline
2012
Back to profit net €21,090 The net result is €21,090, after one loss-making year.
Annual accounts 2011 filed PDFfull format · 19 days before the deadline
2011
Weakest financial year net -€20,174 The net result drops to -€20,174, the lowest from 2007 to 2021.
Annual accounts 2010 filed PDFfull format · 1 day late
2010
Annual accounts 2009 filed PDFfull format · 30 days late
2009
Back to profit net €15,811 The net result is €15,811, after one loss-making year.
Annual accounts 2008 filed PDFfull format · 18 days late
2008
Annual accounts 2007 filed PDFfull format · 23 days before the deadline
2007
Annual accounts 2006 filed PDFfull format · 26 days late
2006
Annual accounts 2005 filed PDFfull format
2005
Annual accounts 2004 filed PDFfull format
2002
Annual accounts 2001 filed PDFfull format
2000
Incorporation 21 publications in the Belgian Official Gazette, the last on 14-07-2022
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Purpose according to the articles of association
- PurposeThe purpose describes the activities the company may carry out under its articles.
- “La société a pour objet le conseil pharmaceutique et le contrôle de la qualité,l'achat,la vente,le commerce,la fabrication et l'emballage en…”
6 activities
- La société a pour objet le conseil pharmaceutique et le contrôle de la qualité,l'achat,la vente,le commerce,la fabrication et l'emballage en Belgique et à l'étranger,non seulement de produits pharmaceutiques et de droguerie mais également de produits qui sont analogues ou directement ou indirectement annexes
- La société a également pour objet l'assistance en matière financière,administrative,fiscale,comptable,sociale et juridique ainsi que l'organisation et l'exploitation des entreprises aux points de vue financier,administratif,technique ou autre
- La société peut réaliser son objet pour son propre compte ou pour compte de tiers,selon la manière qui lui paraîtra la plus appropriée
- Elle peut effectuer toutes opérations commerciales,industrielles,financières,mobilières ou immobilières ayant trait,directement ou indirectement à son objet
- La société peut s'intéresser par n'importe quelle voie dans des affaires,entreprises ou sociétés qui ont un objet analogue,similaire ou connexe,qui peuvent faciliter la réalisation de son objet,qui peuvent fournir des matières premières ou qui peuvent faciliter l'écoulement de ses produits
- La société peut également exercer la fonction d'administrateur dans de telles sociétés
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
- “B-7332, Rue Emile Vandervelde 3”
Articles of association, deed of 01-07-2021 (in French)
Inactive
Absorbed by GESTIFAR in July 2022
PHARMA SERVICES is no longer in the KBO register. GESTIFAR took it over in a merger by absorption, published in the Belgian Official Gazette on 14 July 2022.
- Status
- Inactive
- Reason
- Merger by absorptionBelgian Official Gazette, 14 July 2022 · deed
- Absorbed by
- GESTIFAR
- Last annual accounts
- financial year to 31 December 2021
- Last registered office
- Rue Emile Vandervelde 3, 7332 Siraultas published on 14 July 2022
- Legal form
- Private limited company (pre-2019)
- First annual accounts
- financial year 2001